戻る Agenda
New Technologies and New Targets for Immuno-oncology
Session Chair(s)
Shun Lu
Director, Center for Clinical Medicine of Lung Cancer, Shanghai Chest Hospital,
Shanghai Jiaotong University, China
The approval of the first PD-1 antibody officially opened the prelude to contemporary tumor immunotherapy. The development of tumor immune drugs has gradually become one of the themes in the field of medicine. PD-1 antibody drugs are playing a role in increasing types of tumors, bringing new hope to tumor patients. In addition to continuing to mine the value of PD-1/PD-L1 targets, academia and industrial circles are also constantly exploring new tumor immuno-targets. The continuous breakthroughs of new technologies bring more possibilities to the discovery of new Biomarkers and targets. Who will be the next star target? What is the prospect of development? What challenges will it face? We invite domestic leaders in the development of new drugs to share on the research progress and future development trends of new targets for tumor immunology.